The rollout of the Rika plasmapheresis machines is well advanced ... Moving to the operating highlights for CSL Behring on slide 6. The underlying fundamentals of plasma collection remain strong.

The Melbourne-based company on Tuesday posted what chief executive Paul McKenzie described as a robust set of half-year ...

CSL consistency isn’t winning over investors, Ryan Stokes explains the new dump truck dance, and Macquarie’s return on equity ...

ASX health stocks have fallen this week as Chemist Warehouse hits the bourse through its merger with Sigma Healthcare.

Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business.

CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint ...